Review Article|Articles in Press, 100495

PD-1 Inhibitor-Mediated Peripheral Neuropathy

Open AccessPublished:March 07, 2023DOI:
      This paper is only available as a PDF. To read, Please Download here.


      The discovery of immune checkpoint inhibitors (ICIs) has revolutionized the model of antitumor therapy. With the continuous deepening of the research on the mechanism of immunotherapy, immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors and CTLA4/CD28 inhibitors, have been widely used in a variety of tumors. However, the use of ICI can also lead to a series of immune-related adverse events (irAEs). Common immune-related adverse events include gastrointestinal toxicity, pulmonary toxicity, endocrine system toxicity, skin toxicity and so on. Neurological adverse events are relatively rare, but they seriously affect the quality of life and shorten the survival time of patients. This paper reports cases of peripheral neuropathy mediated by PD-1 inhibitors, and retrieves the relevant literatures at home and abroad to summarize the neurotoxicity caused by PD-1 inhibitors, so as to strengthen the awareness of clinicians and patients on neurological adverse reactions and mitigate potential adverse effects of implemented therapies.

      Key words